Skip to main content
. 2020 Nov 20;38(1):47–59. doi: 10.1007/s10585-020-10064-w

Table 8.

The immunohistochemical (IHC) features of 9 patients

NO./age GTN pathological type IHC report Status
1/26 ETT HCG−, HPL+/+−, P63++, P53− NED
2/28 ETT HCG+, HPL+ Lost
3/36 Choriocarcinoma, ETT HCG scattered+, HPL scattered+, P63++, SALL4− NED
4/40 Choriocarcinoma HCG+, HPL− Dead
5/45 ETT HCG extensive+, HPL+, P53− NED
6/26 Choriocarcinoma HCG++, HPL+++, P63− NED
7/42 PSTT HCG+, HPL+, P63+ NED
8/48 Choriocarcinoma, ETT HCG+, HPL partial+, P63 partial+, SALL4− Under treatment after recurrence(sensitive to chemotherapy)
9/46 Choriocarcinoma HCG+, HPL partial+, P53 90%++, p63 little+ Dead

HPL human placental lactogen